Clinical trial
Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or…
NCT00202800 · Corewell Health West, Other · Completed
Key facts
| NCT number | NCT00202800 |
|---|---|
| Title | Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer |
| Official title | Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer |
| Lead sponsor | Corewell Health West, Other |
| Collaborators | Van Andel Research Institute Eli Lilly and Company Industry Battle Creek Health System Mercy Health System Metropolitan Hospital, Michigan Mecosta County General Hospital Munson Medical Center Saint… |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Etoposide |
| Enrollment | 40 |
| Start date | Mar 1, 2002 |
| Primary completion | Sep 1, 2007 |
| Completion | Jan 1, 2011 |
| First posted | Sep 20, 2005 |
| Last update posted | Jun 2, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: